ENDPOINTS

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have received chemotherapy, making ...

Mar 28, 2025 - 19:48
 0
At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label
Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have received chemotherapy, making ...
Read More

Tags:

Previous Article

Amid Trump Cuts, Climate Researchers Wait for the Ax to Fall

Next Article

FDA approves Sanofi's RNAi drug for hemophilia A and B

Related Posts

First meeting of CDC vaccine advisors in the Kennedy era is postponed

First meeting of CDC vaccine advisors in the Kennedy er...

Feb 20, 2025  0

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets

Akeso shares new data for bispecific in cervical cancer...

Mar 21, 2025  0

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Flagship's Ampersand gets Eli Lilly's support in $65M S...

Mar 19, 2025  0